Biotech startups in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Remepy | Ramat Gan | Series A | $36.0M | 2026-08-12 |
| altM | Bangalore | Series A | $10.3M | 2026-11-05 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Tianhu Technology | Minhang | Series A | $29.0M | 2026-07-13 |
| Pandorum Technologies | Bangalore | Series B | $18.0M | 2026-02-09 |
| HITS | Seoul | Series B | $13.5M | 2026-09-28 |
8 rows of the CSV in 5 of its 18 columns.
- The 2,567 biotech startups in Asia have raised $37.8B in total.
- 385 of them closed their most recent round in the last 12 months, $6.0B combined.
- The largest of those rounds is Anew Labs' $290.0M Series A, dated September 2026.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- Qiming Venture Partners is an investor in 17 of them, more than any other fund.
- Health care is the most common other sector, with 2,017 companies (79%).
- 34% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (43% of companies with a recorded size).
- 4 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 2,567| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi, China | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Tushen Zhihe | Tushen Zhihe provides artificial intelligence protein design services. | Artificial intelligence | Minhang, China | Seed | $1.4M | 2026-11-09 | $1.5M | Wuxi Capital, CHENGMEI VENTURES | 11 to 50 | 2023 |
| altM | altM is an alternate materials company. | Biotech | Bangalore, India | Series A | $10.3M | 2026-11-05 | $13.8M | Omnivore, Theia Ventures, Thai Wah Ventures | 11 to 50 | 2022 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Celaid Therapeutics | Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. | Biotech | Tokyo, Japan | Series B | $2.5M | 2026-10-05 | $17.1M | UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners | 1 to 10 | 2020 |
| M-Based | M-Based develops eco-friendly alternative materials made from mycelium, the root structure of mushrooms. | Biotech | Ankara, Turkey | Seed | $700K | 2026-10-01 | $700K | Hatcher+, Sente Ventures, Fark Labs | 1 to 10 | |
| HITS | HITS develops artificial intelligence software for drug discovery and pharmaceutical research. | Artificial intelligence | Seoul, South Korea | Series B | $13.5M | 2026-09-28 | $25.1M | Korea Investment Partners, Capstone Partners, Company K Partners +2 | 11 to 50 | 2020 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Apollon | Apollon develops noninvasive continuous glucose monitoring systems. | Artificial intelligence | Seoul, South Korea | Series A | $3.7M | 2026-09-22 | $6.4M | TIPS Program, KB Investment, TheVentures +2 | 11 to 50 | 2021 |
| QL Biopharma | QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. | Biotech | Beijing, China | Series C | $44.7M | 2026-09-14 | $173.7M | Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 | 101 to 250 | 2018 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai, China | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou, China | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen, China | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Remepy | Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. | Artificial intelligence | Ramat Gan, Israel | Series A | $36.0M | 2026-08-12 | $51.0M | Samsung NEXT, NFX, Vine Ventures +2 | 11 to 50 | 2022 |
| Phil Rivers Technology | Phil Rivers Technology provides AI solutions for pharmaceutical research and development. | Artificial intelligence | Beijing, China | Series A | $29.6M | 2026-08-05 | $57.3M | Insight Capital | 51 to 100 | 2015 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing, China | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| Diyingjia Technology | Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. | Artificial intelligence | Beijing, China | Series C | $3.0M | 2026-07-28 | $32.3M | IDG Capital, Legend Capital, Microsoft Accelerator | 11 to 50 | 2017 |
| Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen, China | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
| Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia, China | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai, China | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang, China | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai, China | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Shanghai, China | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou, China | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. | Biotech | Shuangliu, China | Series A | $13.7M | 2026-06-26 | $13.7M | Legend Capital, Guosheng Capital, Firefly Haoyue | 11 to 50 | 2021 |
| Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen, China | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian, China | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
| ThunderBio Innovation | ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. | Biotech | Jiaxing, China | Series B | $17.7M | 2026-06-15 | $34.6M | Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi | 11 to 50 | 2018 |
| Dioseve | Dioseve produces egg cells using DIOLs to create more reproductive possibilities. | Biotech | Tokyo, Japan | Series A | $6.2M | 2026-06-11 | $15.5M | ANRI, Coral Capital, Archetype Ventures +2 | 11 to 50 | 2021 |
Table 1. Biotech startups in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 2,567.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Shanghai, China | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | New Radiomedicine Technology | New Radiomedicine Technology supplies medical isotopes in China. | Biotech | Chengdu, China | Series E | $145.4M | 2026-04-03 | $330.6M | Chengdu Science and Technology Venture Capital | 101 to 250 | 2016 |
| 3 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 4 | DP Technology | DP Technology applies AI to scientific research and industrial R&D challenges worldwide. | Artificial intelligence | Haidian, China | Series C | $113.9M | 2025-12-24 | $253.7M | Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 | 101 to 250 | 2018 |
| 5 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Shanghai, China | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 6 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi, China | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 7 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai, China | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 8 | Delova Biotech | Delova Biotech develops treatments for pain management. | Biotech | Qixia, China | Series C | $88.6M | 2026-07-22 | $109.8M | Legend Capital, Peakview Capital, Hyfinity Investments +1 | 51 to 100 | 2017 |
| 9 | Zenitar | Zenitar conducts drug research and biomedical technology industrialization. | Biotech | Chengdu, China | Series C | $86.0M | 2026-01-12 | $155.7M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital | 51 to 100 | 2019 |
| 10 | MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian, China | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
Table 2. Biotech startups in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 17 | 1% | 7 | AusperBio, Tianhu Technology, Prime Lifescience |
| 2 | TIPS Program | Startup incubator | Gangneung, South Korea | 14 | 1% | 1 | Apollon |
| 3 | Legend Capital | Venture capital firm | Beijing, China | 12 | 0% | 5 | Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology |
| 4 | Turkey Development Fund | Fund of funds | Umraniye, Turkey | 12 | 0% | 1 | Viseur AI |
| 5 | Matrix Partners China | Venture capital firm | Beijing, China | 11 | 0% | 3 | Alioth, DP Technology, D3 Bio |
| 6 | Kaitai Capital | Venture capital firm | Hangzhou, China | 10 | 0% | 2 | Bivision, Levinthal |
| 7 | BioVenture | Venture capital firm | Suzhou, China | 9 | 0% | 4 | AusperBio, Degron Therapeutics, Essentia Biosciences |
| 8 | Hillhouse Investment | Angel group | Singapore | 9 | 0% | 5 | Etern, UniXell Biotechnology, Dishi Medical |
| 9 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 8 | 0% | 2 | HemaCell, UniXell Biotechnology |
| 10 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 7 | 0% | 2 | MoleculeMind, MAXVAX |
| 11 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 7 | 0% | 1 | HemaCell |
| 12 | IDG Capital | Private equity firm | Beijing, China | 7 | 0% | 3 | Layerwave Bio, Diyingjia Technology, MAXVAX |
| 13 | Gaorong Capital | Venture capital firm | Wangjing, China | 7 | 0% | 3 | BioGeometry, Bivision, Allink Biotherapeutics |
| 14 | CMB International Capital Corporation | Investment bank | Central, Hong Kong | 6 | 0% | 1 | HemaCell |
| 15 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 6 | 0% |
Table 3. Biotech startups in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 2,017 | 79% | $33.8B |
| Software | 249 | 10% | $3.7B |
| Artificial intelligence | 172 | 7% | $2.8B |
| Hardware | 93 | 4% | $241.3M |
| Energy | 22 | 1% | $886.3M |
| Cybersecurity | 19 | 1% | |
| Education | 16 | 1% | $21.8M |
| Commerce | 15 | 1% | $3.0M |
| Fintech | 13 | 1% |
Table 4. Biotech startups in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
Table 6. Biotech startups in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 13 | 3% | $209.6M |
| October 2026 | 23 | 6% | $197.5M |
| September 2026 | 32 | 8% | $900.2M |
| August 2026 | 33 | 9% | $549.8M |
| July 2026 | 42 | 11% | $572.4M |
| June 2026 | 30 | 8% | $399.6M |
| May 2026 | 33 | 9% | $559.3M |
| April 2026 | 21 | 5% | $395.9M |
| March 2026 | 31 | 8% | $494.4M |
| February 2026 | 23 | 6% | $281.3M |
| January 2026 | 43 | 11% | $609.1M |
| December 2025 | 46 | 12% | $735.0M |
| November 2025 | 15 | 4% | $144.7M |
Table 8. Biotech startups in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 324 | 13% | $5.2B |
| 2025 | 316 | 12% | $3.2B |
| 2024 | 336 | 13% | $1.9B |
| 2023 | 330 | 13% | $2.8B |
| 2022 | 294 | 11% | $5.3B |
| 2021 | 274 | 11% | $7.3B |
Table 9. Biotech startups in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 216 | 9% |
| 2020 to 2022 | 649 | 26% |
| 2015 to 2019 | 1,004 | 40% |
| 2010 to 2014 | 376 | 15% |
| Before 2010 | 270 | 11% |
Table 10. Biotech startups in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 507 | 24% |
| 11 to 50 | 907 | 43% |
| 51 to 100 | 335 | 16% |
| 101 to 250 | 208 | 10% |
| 251 to 500 | 73 | 3% |
| 501 to 1,000 | 57 | 3% |
| 1,001 to 5,000 | 28 | 1% |
| 5,001 to 10,000 | 4 | 0% |
| 10,001 or more | 2 | 0% |
Table 11. Biotech startups in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Asia. On 16 November 2026 that is 2,567 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 2,567 rows: 920 have no round amount, 0 no city and 1,048 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Asia are on the list?
- 2,567, in the file dated 16 November 2026. 385 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 2,567 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.